Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines, and animal health products. The companyâ€™s operations are principally managed on a product basis, encompassing two operating segments: pharmaceutical and animal health. The pharmaceutical segment includes human health pharmaceutical and vaccine products, while the animal health segment discovers, develops, manufactures, and markets a wide range of veterinary pharmaceutical and vaccine products. Merck has made disciplined investments to leverage leading-edge science and advanced its broad pipeline, which includes growing diversity across new therapeutic areas and modalities. The company continues to execute strategic business development opportunities to augment its internal pipeline with compelling external science. Merck's performance during 2023 reflects strong execution of its science-led strategy, benefiting from strong underlying demand across its innovative portfolio. The company has entered into global development and commercialization agreements and has made acquisitions to enhance its capabilities in precision medicine and oncology. Merck's capital allocation strategy prioritizes investments in its business to drive near- and long-term growth, including addressing important unmet medical needs and supporting commercial opportunities. The company remains committed to pursuing value-enhancing business development transactions and has seen significant increases in research and development expenses, reflecting higher charges for business development transactions and increased development spending in therapeutic areas such as oncology and vaccines. Merck's strong financial profile enables it to fund research and development, finance acquisitions and external alliances, and maximize upcoming launches while providing significant cash returns to shareholders. The company anticipates that its sources of financing will be adequate to meet its future requirements, with cash provided by operating activities serving as the primary source of funds for operating needs. Merck's strategic management practices include evaluating investment opportunities and resource allocation to enhance operational efficiency and firm performance. The company actively monitors the landscape for growth opportunities that meet its strategic criteria, focusing on the coordination of its assets and internal processes to support and enhance business strategies. Merck's IT capabilities are integral in mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities, underscoring the importance of information management capability to provide data and information to users with appropriate levels of accuracy, timeliness, reliability, and security. The company continues to invest in technology infrastructure and digital transformation to enhance its operational flexibility and market responsiveness, ensuring that it remains a competitive force in the health care industry.